

calcium acetate 667mg hard capsules (PhosLo) (No: 601/10)
Fresenius Medical Care (UK) Ltd

Product Update

15 January 2010

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

calcium acetate (PhosLo) is accepted for use in NHS Scotland for prevention/treatment of hyperphosphataemia in patients with advanced renal failure on dialysis.

For patients in whom calcium acetate is an appropriate phosphate binding agent this product is available at a cost per unit of calcium equivalent to that of an existing preparation.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 10 November 2009.

Chairman
Scottish Medicines Consortium